Pharmaceuticals

The pharmaceutical industry is constantly evolving. Whilst small molecules still dominate the pharmacopeia, the role and market share of biologics is ever increasing. Whilst identifying novel therapeutics remains of primary importance, re-formulation and optimisation of existing drugs provides opportunities to improve efficacy and pharmacology. Furthermore, the genomic era is bringing in new opportunities for personalised medicine. In essence it is an exciting and challenging time, and our pharmaceutical team has the knowledge and experience to provide the service that you demand.

Our attorneys work with clients across the full ambit of the pharmaceutical field including blue chip pharmaceutical companies, academic institutions and their spin-outs. We understand the science, the legal and regulatory issues, and also the commercial environment in which you operate. Whatever your technology and business model we have the people to protect, manage and enforce your intellectual property. For example, our attorneys have a wealth of experience in:

• Small molecule NCEs 
• Biologics, including antibodies and nucleic acid based therapies
• Formulation technologies, including polymorphs, crystallisation and co-crystallisation, isomers, salts, and excipients
• Delivery systems, including customised release systems, implantables, trans-dermal systems, and gene therapy vectors
• Dosage regimes
• Cell-based therapies

For several of our clients, one particularly highly valued aspect of our service offering is the ability to put together a team to assist your in-house IP department working within whatever framework suits you, or seconding an attorney to work with you on site. We understand that patents are the lifeblood of your companies, and that you demand the best service possible.

If you would like to discuss how exactly we can help you, call me directly at +44 (0) 141 307 8400 or send an email to russell.thom@murgitroyd.com.

Russell Thom

Director, Patents